Cargando…

Contemporary survival and anticoagulation of patients with atrial fibrillation: A community based cohort study in China

BACKGROUNDS: The understanding of death in patients with atrial fibrillation (AF) in China is limited. This study aimed to assess the contemporary survival of AF patients in China and to explore risk factors for deaths. METHODS: This was a prospective community-based cohort study including 559 AF pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Yong, Zeng, Qingye, Cai, Lidong, Wang, Xingjie, Wang, Bin, Shen, Chaoying, Li, Chao, Wang, Caihong, Shen, Yahong, Yang, Shunhong, Wu, Xiaoyu, Liu, Yan, Xu, Juan, Lu, Xiaofeng, Chen, Songwen, Zhou, Genqing, Liu, Shaowen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363600/
https://www.ncbi.nlm.nih.gov/pubmed/35966522
http://dx.doi.org/10.3389/fcvm.2022.911393
_version_ 1784764961354940416
author Wei, Yong
Zeng, Qingye
Cai, Lidong
Wang, Xingjie
Wang, Bin
Shen, Chaoying
Li, Chao
Wang, Caihong
Shen, Yahong
Yang, Shunhong
Wu, Xiaoyu
Liu, Yan
Xu, Juan
Lu, Xiaofeng
Chen, Songwen
Zhou, Genqing
Liu, Shaowen
author_facet Wei, Yong
Zeng, Qingye
Cai, Lidong
Wang, Xingjie
Wang, Bin
Shen, Chaoying
Li, Chao
Wang, Caihong
Shen, Yahong
Yang, Shunhong
Wu, Xiaoyu
Liu, Yan
Xu, Juan
Lu, Xiaofeng
Chen, Songwen
Zhou, Genqing
Liu, Shaowen
author_sort Wei, Yong
collection PubMed
description BACKGROUNDS: The understanding of death in patients with atrial fibrillation (AF) in China is limited. This study aimed to assess the contemporary survival of AF patients in China and to explore risk factors for deaths. METHODS: This was a prospective community-based cohort study including 559 AF patients, who were followed-up from July 2015 to December 2020. RESULTS: During 66-month follow-up, there were 200 deaths (56.5% cardiovascular, 40.0% non-cardiovascular, and 3.5% unknown causes) among 559 AF patients with the median age of 76 years. The top three causes of death were heart failure (33.0%), ischemic stroke (17.0%) and cancer (16.5%). Multivariate Cox regression analysis indicated baseline variables positively associated with all-cause death were age (HR: 1.10, 95% CI: 1.08–1.13), AF subtype (HR: 1.37, 95% CI: 1.08–1.73), prior myocardial infarction (HR: 3.40, 95% CI: 1.48–7.78), previous tumor (HR: 2.61, 95% CI: 1.37–4.98), hypoglycemic therapy at baseline (HR: 1.81, 95% CI: 1.13–2.91), but body weight (HR: 0.98, 95% CI: 0.97–1.00) and use of calcium channel blocker (CCB) (HR: 0.62, 95% CI: 0.41–0.95) played a protective role to all-cause death. Of patients who were alive at the end of follow-up, 24.0% were on oral anticoagulants (OAC) alone, 4.5% on dual antithrombotic therapy, 33.1% on antiplatelet agents alone and 38.4% weren't on any antithrombotic medication. CONCLUSION: Ischemic stroke still remains one of the leading causes of death and OAC is seriously underused in AF patients in China. Independent risk factors for death are age, AF subtype, previous tumor, prior myocardial infarction, hypoglycemic therapy, low body weight and no CCB use. CLINICAL TRIAL REGISTRATION: http://www.chictr.org.cn/ (ChiCTR-ICR-15007036).
format Online
Article
Text
id pubmed-9363600
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93636002022-08-11 Contemporary survival and anticoagulation of patients with atrial fibrillation: A community based cohort study in China Wei, Yong Zeng, Qingye Cai, Lidong Wang, Xingjie Wang, Bin Shen, Chaoying Li, Chao Wang, Caihong Shen, Yahong Yang, Shunhong Wu, Xiaoyu Liu, Yan Xu, Juan Lu, Xiaofeng Chen, Songwen Zhou, Genqing Liu, Shaowen Front Cardiovasc Med Cardiovascular Medicine BACKGROUNDS: The understanding of death in patients with atrial fibrillation (AF) in China is limited. This study aimed to assess the contemporary survival of AF patients in China and to explore risk factors for deaths. METHODS: This was a prospective community-based cohort study including 559 AF patients, who were followed-up from July 2015 to December 2020. RESULTS: During 66-month follow-up, there were 200 deaths (56.5% cardiovascular, 40.0% non-cardiovascular, and 3.5% unknown causes) among 559 AF patients with the median age of 76 years. The top three causes of death were heart failure (33.0%), ischemic stroke (17.0%) and cancer (16.5%). Multivariate Cox regression analysis indicated baseline variables positively associated with all-cause death were age (HR: 1.10, 95% CI: 1.08–1.13), AF subtype (HR: 1.37, 95% CI: 1.08–1.73), prior myocardial infarction (HR: 3.40, 95% CI: 1.48–7.78), previous tumor (HR: 2.61, 95% CI: 1.37–4.98), hypoglycemic therapy at baseline (HR: 1.81, 95% CI: 1.13–2.91), but body weight (HR: 0.98, 95% CI: 0.97–1.00) and use of calcium channel blocker (CCB) (HR: 0.62, 95% CI: 0.41–0.95) played a protective role to all-cause death. Of patients who were alive at the end of follow-up, 24.0% were on oral anticoagulants (OAC) alone, 4.5% on dual antithrombotic therapy, 33.1% on antiplatelet agents alone and 38.4% weren't on any antithrombotic medication. CONCLUSION: Ischemic stroke still remains one of the leading causes of death and OAC is seriously underused in AF patients in China. Independent risk factors for death are age, AF subtype, previous tumor, prior myocardial infarction, hypoglycemic therapy, low body weight and no CCB use. CLINICAL TRIAL REGISTRATION: http://www.chictr.org.cn/ (ChiCTR-ICR-15007036). Frontiers Media S.A. 2022-07-27 /pmc/articles/PMC9363600/ /pubmed/35966522 http://dx.doi.org/10.3389/fcvm.2022.911393 Text en Copyright © 2022 Wei, Zeng, Cai, Wang, Wang, Shen, Li, Wang, Shen, Yang, Wu, Liu, Xu, Lu, Chen, Zhou and Liu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Wei, Yong
Zeng, Qingye
Cai, Lidong
Wang, Xingjie
Wang, Bin
Shen, Chaoying
Li, Chao
Wang, Caihong
Shen, Yahong
Yang, Shunhong
Wu, Xiaoyu
Liu, Yan
Xu, Juan
Lu, Xiaofeng
Chen, Songwen
Zhou, Genqing
Liu, Shaowen
Contemporary survival and anticoagulation of patients with atrial fibrillation: A community based cohort study in China
title Contemporary survival and anticoagulation of patients with atrial fibrillation: A community based cohort study in China
title_full Contemporary survival and anticoagulation of patients with atrial fibrillation: A community based cohort study in China
title_fullStr Contemporary survival and anticoagulation of patients with atrial fibrillation: A community based cohort study in China
title_full_unstemmed Contemporary survival and anticoagulation of patients with atrial fibrillation: A community based cohort study in China
title_short Contemporary survival and anticoagulation of patients with atrial fibrillation: A community based cohort study in China
title_sort contemporary survival and anticoagulation of patients with atrial fibrillation: a community based cohort study in china
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363600/
https://www.ncbi.nlm.nih.gov/pubmed/35966522
http://dx.doi.org/10.3389/fcvm.2022.911393
work_keys_str_mv AT weiyong contemporarysurvivalandanticoagulationofpatientswithatrialfibrillationacommunitybasedcohortstudyinchina
AT zengqingye contemporarysurvivalandanticoagulationofpatientswithatrialfibrillationacommunitybasedcohortstudyinchina
AT cailidong contemporarysurvivalandanticoagulationofpatientswithatrialfibrillationacommunitybasedcohortstudyinchina
AT wangxingjie contemporarysurvivalandanticoagulationofpatientswithatrialfibrillationacommunitybasedcohortstudyinchina
AT wangbin contemporarysurvivalandanticoagulationofpatientswithatrialfibrillationacommunitybasedcohortstudyinchina
AT shenchaoying contemporarysurvivalandanticoagulationofpatientswithatrialfibrillationacommunitybasedcohortstudyinchina
AT lichao contemporarysurvivalandanticoagulationofpatientswithatrialfibrillationacommunitybasedcohortstudyinchina
AT wangcaihong contemporarysurvivalandanticoagulationofpatientswithatrialfibrillationacommunitybasedcohortstudyinchina
AT shenyahong contemporarysurvivalandanticoagulationofpatientswithatrialfibrillationacommunitybasedcohortstudyinchina
AT yangshunhong contemporarysurvivalandanticoagulationofpatientswithatrialfibrillationacommunitybasedcohortstudyinchina
AT wuxiaoyu contemporarysurvivalandanticoagulationofpatientswithatrialfibrillationacommunitybasedcohortstudyinchina
AT liuyan contemporarysurvivalandanticoagulationofpatientswithatrialfibrillationacommunitybasedcohortstudyinchina
AT xujuan contemporarysurvivalandanticoagulationofpatientswithatrialfibrillationacommunitybasedcohortstudyinchina
AT luxiaofeng contemporarysurvivalandanticoagulationofpatientswithatrialfibrillationacommunitybasedcohortstudyinchina
AT chensongwen contemporarysurvivalandanticoagulationofpatientswithatrialfibrillationacommunitybasedcohortstudyinchina
AT zhougenqing contemporarysurvivalandanticoagulationofpatientswithatrialfibrillationacommunitybasedcohortstudyinchina
AT liushaowen contemporarysurvivalandanticoagulationofpatientswithatrialfibrillationacommunitybasedcohortstudyinchina